Compare BioNTech SE - ADR (BNTX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs State Street SPDR S&P Homebuilders ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while State Street SPDR S&P Homebuilders ETF trades at $107.68. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | XHB | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $121.36 |
52-Week Low | $83.89 | $94.86 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
XHB trades at $107.07, down 1.42% amid bearish technical signals, with support at $104 and resistance at $110. The ETF faces mixed housing data with declining existing home sales but potential tailwinds from new housing legislation. Key indicators show oversold short-term RSI but strong bearish momentum from ADX.
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though legislative support for homebuilders offers upside. Risks include interest rate sensitivity and economic slowdowns. Analyst sentiment is neutral with focus on housing market recovery timing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
